R3ACT: This phase I/II trial is evaluating the utility of T-Lymphocyte infusions in stem cell transplant patients who are unresponsive to standard therapyPhase I/II clinical trial to assess the safety and biological efficacy of treatment with virus-specific, cytotoxic T-lymphocytes from partially matched third-party unrelated donors, in stem cell transplant patients with viral reactivation unresponsive to standard therapy (Other ID's: U1111-1140-8324 )

Inclusion

1. Recipients of myeloablative or non-myeloablative allogeneic transplantation for any indication.

2. Viral reactivation or infection with CMV, Adv or EBV as determined by:
A) CMV
- CMV detectable by antigen detection, PCR or culture in peripheral blood or tissue biopsy or by immunohistochemical staining on tissue biopsy specimen
B) Adv
- Presence of Adv as detected by PCR, antigen detection or culture in body fluids including blood, stool, urine or nasopharyngeal secretions
C) EBV
- Elevated EB virus detectable in peripheral blood by PCR or
- Presence of documented EBV related PTLD diagnosed by tissue biopsy or
- Elevated EB virus detectable in the blood by PCR and clinical or imaging findings consistent with EBV lymphoma

3. Failure of standard therapy as defined by:
A) CMV
- The continued presence of detectable CMV virus or antigen after at least 14 days of antiviral therapy with IV ganciclovir or foscarnet
- Recurrence of detectable CMV virus or antigen after at least 2 weeks of prior antiviral therapy
B) Adv
- A rise or less than 50% reduction in viral load in blood or any site of disease as measured by PCR or any quantitative assay despite use of therapy as determined by the treating physician (standard therapy may include intravenous cidofovir within the limits of renal function)
C) EBV
- Increase or less than 50% decrease in the size of EBV lymphoma or
- Increase or less than 50% decrease in the EBV viral load in peripheral blood despite use of appropriate therapy as determined by the treating physician which may include:
- Reduction in immunosuppression
- Rituximab 375mg/m2 up to 4 infusions
- Cytotoxic chemotherapy

4. Adequate hepatic and renal function (< 3 x upper limit of normal for AST (SGOT), ALT (SGPT), < 2 x upper limit of normal for total bilirubin, serum creatinine)

5. ECOG status 0 to 3

6. Patient (or legal representative) has given informed consent.